Literature DB >> 21125344

Tonsillar CD4+FOXP3+ T-regulatory cell dynamics in primary EBV infection.

Yen-Hung Chow1, Hsuen-Wen Chang, Raymond Sia, Pele Chong, Charles Sia.   

Abstract

CD8(+) lymphocytosis is recognized as the primary immunopathological response generated in primary EBV infection that may manifest itself as a benign lymphoproliferative disorder, infectious mononucleosis (IM). While CD4(+)FOXP3(+) T-regulatory cells (Treg cells) are well accepted to inhibit T-cell responses, it is puzzling why massive expansion of CD8(+) lymphocytes still occurs despite CD4(+)FOXP3(+) Treg cells are localized in tonsils, which are the port of entry of the virus. Understanding the interplay between the virologic and immunologic events that take place in tonsils in primary EBV infection is necessary to comprehend why IM preferentially develops in adolescents and the dynamics of CD4(+) Treg cell change that may occur in virus/pathogen infection in a broader setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21125344     DOI: 10.1007/s12026-010-8174-x

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  44 in total

Review 1.  CD69 is an immunoregulatory molecule induced following activation.

Authors:  David Sancho; Manuel Gómez; Francisco Sánchez-Madrid
Journal:  Trends Immunol       Date:  2005-03       Impact factor: 16.687

2.  Fueling regulation: IL-2 keeps CD4+ Treg cells fit.

Authors:  Kevin J Maloy; Fiona Powrie
Journal:  Nat Immunol       Date:  2005-11       Impact factor: 25.606

Review 3.  Morphology, function and pathology of follicular dendritic cells.

Authors:  Y Imal; M Yamakawa
Journal:  Pathol Int       Date:  1996-11       Impact factor: 2.534

4.  CD4+CD25high regulatory cells in human peripheral blood.

Authors:  C Baecher-Allan; J A Brown; G J Freeman; D A Hafler
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

5.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

6.  EBV strain variation: geographical distribution and relation to disease state.

Authors:  M Abdel-Hamid; J J Chen; N Constantine; M Massoud; N Raab-Traub
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

7.  Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220.

Authors:  J E Tanner; C Alfieri; T A Chatila; F Diaz-Mitoma
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Polymorphism of the IL-1 gene complex in Epstein-Barr virus seronegative and seropositive adult blood donors.

Authors:  M Hurme; M Helminen
Journal:  Scand J Immunol       Date:  1998-09       Impact factor: 3.487

9.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.

Authors:  Victoria A Pudney; Alison M Leese; Alan B Rickinson; Andrew D Hislop
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

10.  CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status.

Authors:  Audrey L Kinter; Margaret Hennessey; Alicia Bell; Sarah Kern; Yin Lin; Marybeth Daucher; Maria Planta; Mary McGlaughlin; Robert Jackson; Steven F Ziegler; Anthony S Fauci
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

View more
  1 in total

Review 1.  CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution.

Authors:  Andrea De Maria; Andrea Cossarizza
Journal:  J Transl Med       Date:  2011-06-16       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.